Bioventus Inc. logo

Bioventus Inc. (BVS)

Market Closed
12 Dec, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
7. 55
+0.13
+1.75%
$
511.99M Market Cap
- P/E Ratio
0% Div Yield
159,620 Volume
- Eps
$ 7.42
Previous Close
Day Range
7.42 7.7
Year Range
5.81 11.59
Want to track BVS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 87 days
Bioventus Inc. (BVS) Q3 2025 Earnings Call Transcript

Bioventus Inc. (BVS) Q3 2025 Earnings Call Transcript

Bioventus Inc. ( BVS ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants David Crawford - Vice President of Investor Relations & Treasurer Robert Claypoole - President, CEO & Director Mark Singleton - Senior VP & CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Ross Osborn - Cantor Fitzgerald & Co., Research Division Caitlin Cronin - Canaccord Genuity Corp., Research Division Presentation Operator Good day, and welcome to the Bioventus Inc. Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

Seekingalpha | 1 month ago
Bioventus Inc. (BVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Bioventus Inc. (BVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Bioventus Inc. (NASDAQ:BVS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Mark Singleton - Senior VP & CFO Presentation Unknown Analyst Thanks, everyone, for joining us. Before we begin, just the disclaimer.

Seekingalpha | 3 months ago
Bioventus Inc. (BVS) Q2 2025 Earnings Call Transcript

Bioventus Inc. (BVS) Q2 2025 Earnings Call Transcript

Bioventus Inc. (NASDAQ:BVS ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants David Crawford - Vice President of Investor Relations & Treasurer Mark L. Singleton - Senior VP & CFO Robert E.

Seekingalpha | 4 months ago
Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates

Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates

Bioventus (BVS) came out with quarterly earnings of $0.21 per share, missing the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.19 per share a year ago.

Zacks | 4 months ago
Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript

Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript

Bioventus Inc. (NASDAQ:BVS ) Q1 2025 Results Conference Call May 6, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Robbie Marcus - JPMorgan Operator Good day, and welcome to the Bioventus First Quarter 2025 Conference Call. [Operator Instructions] Please note this event is being recorded.

Seekingalpha | 7 months ago
Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates

Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates

Bioventus (BVS) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago.

Zacks | 7 months ago
4 Healthcare Stocks to Buy as the Sector Faces Government Heat

4 Healthcare Stocks to Buy as the Sector Faces Government Heat

Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.

Zacks | 7 months ago
Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now

Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now

Bioventus (BVS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks | 8 months ago
Bioventus (BVS) Upgraded to Buy: Here's What You Should Know

Bioventus (BVS) Upgraded to Buy: Here's What You Should Know

Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 9 months ago
Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript

Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript

Bioventus Inc. (NASDAQ:BVS ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Caitlin Cronin - Canaccord Genuity Operator Good morning and welcome to the Bioventus Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.

Seekingalpha | 9 months ago
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million

Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million

On Tuesday, Bioventus Inc. BVS reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents.

Benzinga | 9 months ago
Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates

Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates

Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.

Zacks | 9 months ago
Loading...
Load More